| THE BRIGHAM AND WOMEN'S HOSPITAL, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120128697 | NOTCH Inhibition in the Treatment or Prevention of Atherosclerosis - The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and for measuring levels of amount, function, or activity of NOTCH pathway components in biological samples. | 05-24-2012 |
| 20120107365 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 05-03-2012 |
| 20120101042 | Agents and Methods for Tissue Repair and Regeneration - Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described. | 04-26-2012 |
| 20120089030 | SYSTEM AND METHOD FOR CHARACTERIZATION OF ORAL, SYSTEMIC AND MUCOSAL TISSUE UTILIZING RAMAN SPECTROSCOPY - A method and system for characterizing tissue includes a probe connected to a red LASER source and a Raman spectroscope. The probe includes at least excitation fiber and one or more emission fibers that connect the probe with the LASER source and the Raman spectroscope. The excitation fiber is connected to the red LASER source and terminates in the first end of the probe adjacent the tip of the probe. The emission fibers are connected to the Raman spectroscope and terminate in the first end of the probe adjacent the tip of the probe. In one embodiment, the excitation fiber extends through the central portion of the probe and one or more emission fibers are arranged around the excitation fiber. The tip of the probe is intended to come in contact with the tissue to be examined. The tip includes a central opening to allow red LASER radiation to project out of the end of the red excitation fiber on to the tissue and to permit Raman spectra to enter the emission fiber(s) and travel to the Raman spectroscope. The tip is constructed to have a predefined focal length to position the first end of the probe a predefined distance from the surface of the tissue being examined. The tip can be removable and tips having different focal lengths can be used to accommodate different types of tissues and examinations. A detector can convert the Raman spectra into signals and data for analysis by a computer system. The Raman spectra for tissue in a predefined location can be profiled such that the system can distinguish between healthy and diseased tissue. | 04-12-2012 |
| 20120080592 | METHOD AND SYSTEM FOR SURFACE SAMPLING - A system and sampling probe adaptable to an ultrasonic surgical instrument applies irrigation fluid and ultrasonic or vibrational energy to a target, and aspirates material desorbed from the target into a pick-up conduit. A suction source at the distal end of the conduit may aspirate the material released from the target with the irrigation fluid, thus efficiently sampling a broad range of materials from an arbitrary target to produce an analyzable effluent analyte stream which may be ionized and provided to the inlet of an ion-type analysis instrument, or may be fed directly to an instrument such as a flow cytometer, IR or fluorescence spectrophotometer, or other analyzer. Carrier gas may be provided to more effectively transport the desorbed material, and the probe may be incorporated into a robotic device to automatically carry out surface imaging or to effect sampling in hazardous environments. | 04-05-2012 |
| 20120077770 | Methods of Diagnosing and Treating Multiple Sclerosis - Methods of using a 15-oxysterol, e.g., 15-ketocholestene (15-KE), 15-ketocholestane (15-KA), and/or 15-hydroxy-cholestene (15-HC), as a biomarker to monitor disease progression in multiple sclerosis (MS), and methods of treating secondary progressive MS (SPMS) using inhibitors of poly(ADP ribose) polymerase-1 (PARP-1). | 03-29-2012 |
| 20120077686 | DIAGNOSIS OF MULTIPLE SCLEROSIS - The present invention relates to methods and kits for diagnosing multiple sclerosis (MS) in a subject. Particularly, the present invention relates to methods and kits for diagnosing a subtype of MS in a subject, the subtype selected from relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and a pathologic sub-type of MS lesions selected from Pattern I and Pattern II MS lesion. | 03-29-2012 |
| 20120076805 | Methods and Compositions for the Generation and Maintenance of Regulatory T Cells - Methods and compositions for generating and maintaining induced regulatory T cells (iTregs) are provided. Methods and compositions for treating an autoimmune disorder, organ transplant rejection, graft versus host disease or allergic or hypersensitivity and inflammation are also provided. | 03-29-2012 |
| 20120064108 | GLYCOCONJUGATE VACCINES - Glycoconjugate vaccines and methods of preparing and using the same are described. | 03-15-2012 |
| 20120040900 | COMPOSITIONS OF AND METHODS OF USING LIGAND DIMERS - Provided herein are ligand dimers, compositions thereof, as well as methods of their use. The ligand dimers provided can comprise at least one ligand to a Her receptor and can be used to force dimerization of specific receptor pairs. The forced dimerization of specific receptor pairs can be used to control (e.g., promote or inhibit) signaling, and, therefore, the ligand dimers provided can also be used in various forms of treatment in which such signaling control is beneficial to a subject. It follows that methods for controlling signaling are provided as are various methods of treatment. | 02-16-2012 |
| 20120034196 | GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF (FRANK) - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance. | 02-09-2012 |
| 20120003737 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided. | 01-05-2012 |
| 20110301239 | USE OF NOVEL LIPID MEDIATORS TO INHIBIT ANGIOGENESIS - The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA or DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. | 12-08-2011 |
| 20110300570 | METHOD AND SYSTEM FOR GENERATING SPATIALLY AND TEMPORALLY CONTROLLABLE CONCENTRATION GRADIENTS - The ability to rapidly generate concentration gradients of diffusible molecules has important applications in many chemical and biological studies. The present invention is directed to methods and systems for generating spatially and temporally controllable concentration gradients of molecules (i.e. proteins or toxins) in a portable microfluidic device. The formation of the concentration gradients can be initiated by an induced forward flow and further optimized during an induced backward flow. The forward and backward flows can be either passively induced and/or actively pumped. The centimeter-length gradients along the microfluidic channel can be spatially and temporally controlled by the backward flow. The gradient profile was stabilized by stopping the flow. In one example, a stabilized concentration gradient of a cardiac toxin, Alpha-cypermethrin, generated according to the invention was used to test the response of HL-1 cardiac cells in the microfluidic device, which correlated with toxicity data obtained from multi-well plates. The invention can be useful for bio-logical and chemical processes that require rapid generation of concentration gradients in a portable microfluidic device. | 12-08-2011 |
| 20110300219 | NANOSTRUCTURES FOR DRUG DELIVERY - The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor. | 12-08-2011 |
| 20110287964 | URINARY BIOMARKERS FOR SENSITIVE AND SPECIFIC DETECTION OF ACUTE KIDNEY INJURY IN HUMANS - The present invention is directed to acute kidney injury biomarkers, and methods and kits comprising the use of agents directed against acute kidney injury biomarkers for facilitating and enhancing the diagnosis of AKI. The present invention is based on the discovery that specific biomarkers are present in urine at higher concentrations in subjects with acute kidney injury (AKI) as compared with subjects that have no symptoms of AKI. The invention is directed to methods for diagnosis of AKI by determining and monitoring the levels of at least one biomarker protein in a biological sample, such as urine. Further, the invention is directed to methods for facilitating the distinction of kidney infection from bladder infection in a subject. | 11-24-2011 |
| 20110287034 | THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS - Genes that are deregulated in cancer stem cells (e.g., melanoma stem cells) are disclosed. Methods which involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes are used to treat individuals having melanoma. Cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. | 11-24-2011 |
| 20110274703 | DETECTION AND TREATMENT OF NON-DERMAL FIBROSIS - The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis. | 11-10-2011 |
| 20110274700 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as | 11-10-2011 |
| 20110269685 | PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair. | 11-03-2011 |
| 20110268804 | TARGETING OF ANTIGEN PRESENTING CELLS WITH IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. | 11-03-2011 |
| 20110245107 | SELECTIVE DIFFERENTIATION, IDENTIFICATION, AMD MODULATION OF HUMAN TH17 CELLS - The embodiments provide for the modulation of both the differentiation and activity of human TH17 cells. More specifically, human TH17 cell differentiation can modulated by TGF-? and IL-21, and their agonists and antagonists. Function of TH17 cells can be modulated by, for example, BLT1 or podoplanin, and their agonists and antagonists. Additionally, the embodiments provide for the identification of TH17 cells. More specifically, human TH17 cells specifically upregulate BLT1 and podoplanin. | 10-06-2011 |
| 20110213012 | Treatment of Cancers Characterized by Chromosomal Rearrangement of the NUT Gene - The present invention is directed, inter alia, to methods of treating NUT midline carcinoma (NMC) by administering compounds that promote increased histone acetylation. The invention also includes assay methods for determining the responsiveness of NMC to specific histone deacetylases and other compounds. | 09-01-2011 |
| 20110212501 | 3-DIMENSIONAL MULTI-LAYERED HYDROGELS AND METHODS OF MAKING THE SAME - Embodiments of the invention provide three dimensional multi-layered hydrogel constructs with embedded channels, living cells and bioactive agents, and methods for making three dimensional multi-layered hydrogel constructs. The constructs can have bioactive agents to support the living cells. The multi-layered constructs can have channels for perfusion purposes and layers of different hydrogel materials. | 09-01-2011 |
| 20110206667 | POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT - This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid. | 08-25-2011 |
| 20110192974 | Preparation of Test Plates for Matrix Assisted Laser Desorption Ionization - The present invention is directed, sample test plates that can be used in matrix assisted laser desorption ionization. These plates have an etched surface and a layer of MALDI matrix material. The invention also includes methods for making these sample test plates and to methods for using the plates in the MS imaging of cell and tissue samples. | 08-11-2011 |
| 20110189151 | COMPOSITIONS AND METHODS FOR PROLONGING SURVIVAL OF PLATELETS - The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis. | 08-04-2011 |
| 20110172785 | COMPLIANT COMPOSITES FOR APPLICATION OF DRUG-ELUTING COATINGS TO TISSUE SURFACES - A compliant composite for delivering a bioactive agent including a scaffolding material and a polymer coating that together can be attached to compliant tissue surfaces is disclosed, along with methods for constructing and applying these composites. In some embodiments, the composite further comprises a barrier layer for localized delivery of the bioactive agent. | 07-14-2011 |
| 20110171210 | HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE - The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells. | 07-14-2011 |
| 20110168177 | Anesthesia Simulator and Controller for Closed-Loop Anesthesia - Methods, systems, and software are disclosed for simulating and controlling anesthesia delivery and for implementing automatic closed-loop anesthesia with an inhaled anesthetic agent. The methods involve using a physiological simulation to forward calculate the effects of an inhaled anesthetic agent, and searching for gas administration characteristics, such as fresh gas flow rates and anesthetic concentrations or partial pressures, that will achieve a desired physiological anesthetic concentration or effect with minimal use of anesthetic agent and minimal fresh gas flow rate. | 07-14-2011 |
| 20110165149 | TARGETING ABCB5 FOR CANCER THERAPY - The invention related to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | 07-07-2011 |
| 20110152305 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 06-23-2011 |
| 20110152249 | EVALUATING CENTRAL NERVOUS SYSTEM - Evaluating hemodynamic parameters in the cortex can be used as an objective test for CNS activity, e.g., pain. | 06-23-2011 |
| 20110150880 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES - The invention relates to the compositions of synthetic oligo-β-(1→6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same. | 06-23-2011 |
| 20110144476 | Integrated Surgical Sampling Probe - The present invention is directed to devices for collecting tissue samples from patients. The devices create tissue fragments which are then collected by aspiration. The devices include signal emitters that allow the exact position where a biopsy sample was obtained to be determined. In addition the invention includes methods for obtaining tissue samples using these devices. | 06-16-2011 |
| 20110143993 | ENDOTHELIAL BASEMENT MEMBRANE TARGETING PEPTIDE LIGANDS - Peptides that selectively bind to antigens exposed in vascular disease or dysfunction have been identified by biopanning a phage library. The ligands are useful when attached to a substrate to be in contact with endothelial surfaces, especially those where drug delivery is utilized, such as following angioplasty, with release from a drug delivery reservoir in a medical device such as a stent, or by administration intravenously in the form of nano or microparticles, although the peptides may also be used with other medical devices or substrates, for targeting or to increase adhesion to endothelial surfaces. The nanoparticle technology can be used to treat injured vasculature, a clinical problem of primary importance. The targeted nanoparticles are also useful in the treatment of other diseases and disorders such as oncologic and regenerative diseases and indications where neoangiogenesis is commonly observed. | 06-16-2011 |
| 20110110923 | FISH ASSAY FOR EML4 AND ALK FUSION IN LUNG CANCER - Methods and compositions provided relate to conducting a FISH assay for detecting a chromosomal inversion between EML4 and ALK. The FISH assay described herein is useful for diagnostic and prognostic purposes, as well as for determination of therapeutic strategies. | 05-12-2011 |
| 20110106113 | SYSTEM AND METHOD FOR HERNIA MESH FIXATION - The invention includes a surgical fastener and associated deployment system and method that overcomes the drawbacks of prior art surgical mesh fixation devices. The surgical fastener and deployment system may be used to fixate a surgical mesh material to the abdominal wall for the purpose of hernia repair. In accordance with one embodiment, the fastener may include an anchor head comprising a bi-pyramid framework. The anchor head is preferably made from a highly deformable and biocompatible material that withstands high flexural strain within an oscillatory environment. The anchor head may be provided in an elongate, undeployed configuration, and then expanded during deployment into a second, generally planar configuration. The anchor head may be biased to expand into the generally planar configuration from the undeployed configuration in a variety of manners. | 05-05-2011 |
| 20110081362 | TREATMENT OF CANCER - Described herein are methods based, in part, on the discovery of genes or gene products that can be down-modulated to inhibit the growth and survival of a cell, such as a cancer cell. In one embodiment, the genes or gene targets are preferentially expressed in a cell having an activating Ras mutation (e.g., a cancer cell), which permits selective inhibition of growth in cells bearing an activating Ras mutation without affecting cells lacking enhanced Ras activity. In addition, the methods described herein provide for determining cancer prognosis in an individual bearing an activating Ras mutation. | 04-07-2011 |
| 20110070205 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49 | 03-24-2011 |
| 20110065807 | PH SENSITIVE BIODEGRADABLE POLYMERIC PARTICLES FOR DRUG DELIVERY - The present invention generally relates to polymers and particles, such as nanoparticles. The particles and polymers generally include one or more buffering components. Additionally, the particles and polymers may include two or more components that impart useful properties (functionalities). The particles and polymers, for example, may include a buffering component and a degradable component. As described herein, the particles and polymers may also include a hydrophilic component and/or a cleavable bond component. The particles and polymers described herein have been found to be particularly effective when used for delivery of one or more agents, such as one or more pharmaceutical agents. Other aspects of the invention are directed to methods of using or administering such particles or polymers, kits involving such particles or polymers, and the like. The present invention also relates to particles containing a cleavable bond component and one or more fluorescence resonance energy transfer (FRET) pairs as well as methods of detecting the cleavage of the cleavable bond component of such particles. | 03-17-2011 |
| 20110059854 | DIAGNOSTIC AND PROGNOSTIC TESTS - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided. | 03-10-2011 |
| 20110059125 | ZWITTERIONIC IMMUNOMODULATORS FOR THE TREATMENT OF ASTHMA AND ALLERGY - Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo. | 03-10-2011 |
| 20110053930 | INHIBITORS OF THE BMP SIGNALING PATHWAY - The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. | 03-03-2011 |
| 20110052697 | Aptamer-Directed Drug Delivery - The present invention provides systems, methods, and compositions for targeted delivery of a therapeutic agent organs, tissues, cells, extracellular matrix components, and intracellular compartments. The present invention provides a complex comprising a therapeutic or diagnostic agent and a nucleic acid targeting moiety, wherein the agent non-covalently associates with base pairs of the nucleic acid targeting moiety. The invention provides targeted particles comprising a particle and an inventive complex. The present invention provides methods of designing, manufacturing, and using inventive complexes and targeted particles. | 03-03-2011 |
| 20110046234 | Retinaldehyde in the Treatment of Obesity, Diabetes and Other Conditions - The present invention is directed to methods of treating a patient for a disease or condition associated with adipogenesis or insulin resistance by administering a retinaldehyde compound to the patient or a compound that increases endogenous retinaldehyde levels by inhibiting the enzyme retinaldehyde dehydrogenase 1. | 02-24-2011 |
| 20110046209 | RNA-Induced Translational Silencing and Cellular Apoptosis - The invention is directed to RNA molecules that can be used to inhibit protein synthesis and to induce cells to undergo apoptosis. It also includes pharmaceutical compositions containing the RNAs that can be used in treating or preventing tumors; abnormal dermatological growths and viral infections. | 02-24-2011 |
| 20110045508 | Urinary CA125 Peptides as Biomarkers of Ovarian Cancer - The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced. | 02-24-2011 |
| 20110045098 | EXCITATORY GLYCINE RECEPTORS AND METHODS - The invention provides isolated N-methyl-D-aspartate type 3B (NR3B) polypeptides, functional fragments and peptides, encoding nucleic acid molecules and polynucleotides, and specific antibodies. Also provided are excitatory glycine receptors, containing either NR3B or NR3A polypeptides. Further provided are methods for detecting excitatory glycine receptor ligands, agonists and antagonists. The invention also provides related diagnostic and therapeutic methods. | 02-24-2011 |
| 20110045002 | METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION - The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them. | 02-24-2011 |
| 20110034677 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 02-10-2011 |
| 20110028343 | Biomarkers of Ovarian Cancer - The invention is directed to assays for biomarkers associated with ovarian cancer that can be used diagnostically. It includes glass or plastic plates or slides on which the biomarkers have been immobilized and kits containing these plates or slides. | 02-03-2011 |
| 20100303723 | DRUG DELIVERY SYSTEMS USING FC FRAGMENTS - The present invention provides drug delivery systems comprising FcRn binding partners (e.g., FcRn binding partner, Fc fragment) associated with a particle or an agent to be delivered. Inventive drug delivery systems allow for binding to the FcRn receptor and transcytosis into and/or through a cell or cell layer. Inventive systems are useful for delivering therapeutic agents across the endothelium of blood vessels or the epithelium of an organ. | 12-02-2010 |
| 20100298635 | Steerable Capsule Apparatus and Method - A capsule includes a main body with at least one tail connected to the main body. At least two coils are disposed on each tail such that the coils are responsive to a magnetic field interacting with the coils such that a force is exerted on the tail. The capsule is controlled through application of a varying magnetic field with a constant current in the coils and/or by providing varying a current in the coils that interact with a constant magnetic field. The capsule can be disposed in a cavity, and the magnetic field can be provided from outside the cavity to affect movement of the capsule. An MRI device can be configured to control and image the capsule. | 11-25-2010 |
| 20100292154 | PROTEIN PROFILE FOR OSTEOARTHRITIS - The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis (OA). In particular, the invention provides the identity of marker proteins whose expression is correlated with OA and OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents. | 11-18-2010 |
| 20100291042 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided. | 11-18-2010 |
| 20100286164 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF - Aspects of the invention relate to substituted aryl propylamino-oxy-analogs and uses thereof. Aspects of the invention relate to compositions that are inhibitors of γ-secretase and uses thereof for treating subjects having, or at risk of developing, Alzheimer's disease. | 11-11-2010 |
| 20100273859 | TREATMENT AND PREVENTION OF HIV INFECTION - Disclosed herein are methods for treating and/or preventing HIV infection in a cell. The methods involve downmodulating one or more of the HIV-dependency factors (HDFs) disclosed herein to thereby treat and/or prevent HIV infection in the cell. Downmodulating the HDFs can be by contacting the cell with an agent that downmodulates the HDF. Also disclosed herein are methods for treating and/or preventing HIV infection in a subject comprising downmodulating one or more of the HIV-dependency factors (HDFs), disclosed herein, to thereby treat and/or prevent HIV infection in the subject. The method may further comprise selecting a subject diagnosed with or at risk for HIV infection, prior to downmodulating. Downmodulating the HDFs may comprise administering an agent that downmodulates the HDF to the subject such that the agent contacts HIV host cells of the subject. The agent may inhibit HDF gene expression, protein synthesis, HDF function or HDF activity, or combinations thereof. | 10-28-2010 |
| 20100267572 | SPACE EFFICIENT POLYMER SETS - The disclosure features a collection that comprises a plurality of polymers, typically nucleic acid molecules in a compact form. The molecules include all possible sequences or at least a certain percentage of all possible sequences, of a particular length. | 10-21-2010 |
| 20100266491 | SYSTEM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS - The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof. | 10-21-2010 |
| 20100260801 | Polysaccharide vaccine for staphylococcal infections - The invention relates to compositions of the capsular polysaccharide/adhesin (PS/A) of staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. The invention also relates to the use of the PS/A as a vaccine for inducing active immunity to infections caused by | 10-14-2010 |
| 20100227807 | Use of Gelsolin to Diagnose and Treat Inflammatory Desease (Stossel) - The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis). | 09-09-2010 |
| 20100227778 | Diagnosis and Treatment of Noonan Syndrome and Neoplastic Disorders - Methods and compositions for diagnosing and treating Noonan syndrome and neoplastic disorders are provided herein. | 09-09-2010 |
| 20100209536 | Methods and Kits for Use in the Treatment and Prevention of Diseases or Conditions of the Immune System or Infectious Diseases - This invention provides methods of treating and preventing diseases or conditions of the immune system or infectious disease, involving administration of vitamin D and/or one or more antioxidants (e.g., vitamin E and/or zinc). | 08-19-2010 |
| 20100203142 | AMPHIPHILIC COMPOUND ASSISTED NANOPARTICLES FOR TARGETED DELIVERY - The present invention generally relates to nanoparticles with an amphiphilic component. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries. | 08-12-2010 |
| 20100196482 | POLYMER-ENCAPSULATED REVERSE MICELLES - A method for encapsulating nucleic acids, particularly siRNAs, shRNAs, microRNAs, gene therapy plasmids, and other oligonucleotides in biodegradable polymers is disclosed, whereby the nucleic acids are formulated into reverse micelles composed of non-toxic and/or naturally-occurring lipids prior to nanoparticle formation by nanoprecipitation. This method can be coupled to other techniques that improve intracellular drug targeting, ultimately enhancing intracellular delivery of the aforementioned nucleic acids. | 08-05-2010 |
| 20100196264 | USE OF SOMATOSTATIN ANALOGS IN MYOCARDIAL PERFUSION IMAGING - The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject. | 08-05-2010 |
| 20100190860 | METHODS FOR SELECTIVELY ENHANCING ANTINOCICEPTIVE POTENCY OF LOCAL ANESTHETICS - This document features methods related to selectively inducing nociceptor blockade. For example, methods of treating pain by administering antinociceptor agents are provided. | 07-29-2010 |
| 20100190659 | Compositions and Methods for Diagnosing and Assessing Inflammatory Myopathies - The present invention is directed to assay methods for inflammatory myopathies and microarray plates that can be used in carrying out these assays. | 07-29-2010 |
| 20100184950 | PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair. | 07-22-2010 |
| 20100184077 | Allelic Form of the HMGA2 Gene Predisposing Women to the Formation of Leiomyomas - The present invention is directed to diagnostic assays that can be used to determine if a woman carries an allelic form of the HMGA2 gene that predisposes her to the formation of fibroid tumors. The invention also encompasses vectors containing this allele, cells transformed with these vectors and transgenic animals that carry at least one copy of the allele. | 07-22-2010 |
| 20100183658 | Novel Compounds for Enhancing MHC Class II Therapies - The invention provides classes of novel compounds that accelerate peptide loading to DR in the absence of DM and related pharmaceutical compositions. The invention also provides conjugates of these compounds with peptides, antigens or other MHC-based therapeutics, including peptides that self-catalyze their loading onto MHC Class II molecules. Methods are provided for modulating an immune response in a subject. Also disclosed are methods of using the novel compounds, e.g., in combination with MHC-based therapeutics, for the treatment of autoimmune diseases and for the manufacture of medicaments. Methods of improving loading of viral peptides and tumor peptides for enhancing the CD4 T cell response following vaccination against viruses or tumors, and related vaccines, are also provided. | 07-22-2010 |
| 20100167948 | MicroRNA Expression Profiling of Cerebrospinal Fluid - The present invention is directed to assay methods in which the levels of certain specific microRNAs are determined in the cerebrospinal fluid of a subject. These methods may be used in the diagnosis or monitoring of neurological diseases, especially brain tumors. | 07-01-2010 |
| 20100159607 | IL1RL-1 AS A CARDIOVASCULAR DISEASE MARKER AND THERAPEUTIC TARGET - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 06-24-2010 |
| 20100145030 | GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance. | 06-10-2010 |
| 20100144868 | Novel Neuroprotective Compounds and Uses Thereof - Disclosed are novel hybrid compounds having a fullerene core residue, one or more bioavailability enhancing moieties and one or more glutamate receptor ligand residues, whereby the bioavailability enhancing moiety allow the compound to reach an effective concentration in physiological media and pass the blood-brain barrier, as defined in the specification. Also disclosed are pharmaceutical compositions containing these hybrid compounds and uses thereof as antioxidants and/or neuroprotective agents for the treatment of medical conditions associated with oxidative stress and/or neural damage, such as, for example, neurological diseases, disorders and trauma, and hence in the treatment of CNS-associated diseases, disorders and trauma, as well as to uses thereof as antiviral, antibacterial, antiglycemic, antiarrhythmic, antidepressant and antitumor agents. | 06-10-2010 |
| 20100137164 | BIOMARKERS FOR PREDICTING PROSTATE CANCER PROGRESSION - The present invention relates to the identification and use of gene expression profiles with clinical relevance to prostate cancer. In particular, the invention provides the identity of genes whose expression, at the transcriptional and protein levels, is correlated with prostate cancer progression. Methods and kits are described for using these gene expression profiles in the study and/or diagnosis of prostate cancer diseases, in the prediction of prostate cancer progression, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that target these genes or their protein products, in particular for the development of therapeutics for modulating prostate cancer progression. | 06-03-2010 |
| 20100105773 | USE OF RESOLVINS AND DOCOSATRIENES AND ANALOGUES THEREOF FOR THE TREATMENT OF ANGIOGENESIS AND OCULAR NEOVASCULARIZATION - The present invention relates to methods and compositions for the treatment of, or prevention of angiogenesis in a subject. In particular, the present invention relates to methods to treat a subject with, or at risk of developing angiogenesis by administering a pharmaceutical composition comprising a resolvin or resolvin analogue or precursor, and/or a protectin or protectin analogue. In another embodiment, the present invention relates to the use of resolvins and protectins to treat pathologies associated with angiogenesis. | 04-29-2010 |
| 20100099096 | Compositions and Methods for Identifying Factors Affecting Protein Stability - The present invention is directed to retroviral vectors, and libraries generated from the vectors that can be used in assessing the stability of proteins and in correlating degradation with a specific E3 ubiquitin ligase. The libraries can also be used to identify factors that alter the degradation of proteins of therapeutic value and which have potential use clinically. | 04-22-2010 |
| 20100094099 | Instrumented Metered-Dose Inhaler and Methods for Predicting Disease Exacerbations - The present invention is directed to devices, systems, and methods for monitoring inhaled drug usage to predict when an acute attack or exacerbation of a disease, such as a respiratory disease, is imminent. Instrumented inhalers that use modular designs with standard components are disclosed, as are systems for monitoring the instrumented inhalers. Also disclosed are methods for determining whether or not a patient's inhaled drug usage pattern indicates that an acute attack or disease exacerbation is imminent, and notifying appropriate medical personnel of any usage patterns indicative of an attack or disease exacerbation. If such an attack or exacerbation is imminent, additional therapeutic agents may be dispensed to the patient or other interventions made. | 04-15-2010 |
| 20100087358 | NOTCH mutations leading to increased receptor signaling - The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients. | 04-08-2010 |
| 20100086928 | DETECTION OF ORGAN REJECTION - The present invention features methods and compositions for the non-invasive detection of organ rejection using a microRNA score. | 04-08-2010 |
| 20100081684 | METHODS FOR TREATING INFLAMMATORY DISORDERS - The invention described herein is based, in part, on the discovery that thieno[3,2-c]pyridine derivatives prevent inflammation in the setting of inflammatory disorders, such as asthma. Described herein are methods for treating inflammatory disorders including, for example asthma, by administering a thieno[3,2-c]pyridine derivative compound to an individual in need thereof. | 04-01-2010 |
| 20100061992 | THERAPEUTIC USES OF TIM-3 MODULATORS - The invention provides novel methods of treating neurological disorders, including neurodegenerative disorders such as MS. The invention also provides novel methods of treating cancers, including glial tumors such as glioblastoma multiforme. The invention further provides vaccines and related uses. | 03-11-2010 |
| 20100048705 | METHODS OF TREATING AND PREVENTING NEOVASCULARIZATION WITH OMEGA-3 POLYUNSATURATED FATTY ACIDS - Disclosed are methods for treating or preventing ocular neovascularization in a subject at risk. The method comprises administering to the subject an effective amount of omega-3 polyunsaturated fatty acid to thereby treat or prevent the ocular neovascularization. This method is suitable for treating or preventing retinopathy of prematurity, retina vein occlusion, sickle cell retinopathy, choroidal neovascularization, radiation retinopathy, microangiopathy, retinal hyperoxia, diabetic retinopathy, and age related macular degeneration. Preferably the methods are applied to premature infants, especially those exposed to high levels of oxygen, to treat or prevent ocular neovascularization results from retinopathy of prematurity. Preferably, the omega-3 polyunsaturated fatty acid is administered at high dose, periodically (e.g. from birth) over a prolonged period of time, until the eye is fully vascularized, or to the age of 1 year. Appropriate routes of administration include oral and intravenous administration. Suitable omega-3 polyunsaturated fatty acids include docosahexaenoic acid and eicosapentaenoic acid. These agents can be administered in a pharmaceutically acceptable carrier, e.g. one which contains an anti-oxidant for the omega-3 polyunsaturated fatty acid. | 02-25-2010 |
| 20100028876 | DIAGNOSTIC TESTS USING GENE EXPRESSION RATIOS - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from cell or tissue samples, such as cancer cell or tissue samples. The invention also provides sets of genes that are expressed differentially in normal and cancer lung cells and tissues. These sets of genes can be used to discriminate between normal and malignant cells or tissues, and between classes of malignant cells or tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumour progression/regression also are provided. | 02-04-2010 |
| 20100022680 | Microfluidic Synthesis of Organic Nanoparticles - The present invention provides microfluidic systems and methods for the production of particles (e.g., nanoparticles) for drug delivery. The present invention provides microfluidic devices useful for production of particles by nanoprecipitation. The present invention provides highly homogenous compositions of particles produced by inventive microfluidic devices. | 01-28-2010 |
| 20100016938 | DIAGNOSING, MONITORING AND TREATING INFLAMMATION - The present invention provides methods and compositions for treating chronic inflammatory disease in a subject and associated pharmaceutical compositions, medical devices and systems. | 01-21-2010 |
| 20100015687 | Tetracycline Repressor Regulated Oncolytic Viruses - The present invention is directed oncolytic Herpes simplex-1 viruses whose replication is controlled using a tetracycline operator/repressor system. The invention also includes DNA sequences used in making the viruses and methods in which these viruses are used in the treatment of cancer patients with solid tumors. | 01-21-2010 |
| 20090317410 | USE OF ZWITTERIONIC POLYSACCHARIDES FOR THE SPECIFIC MODULATION OF IMMUNE PROCESSES - The invention relates to three-dimensional molecular structure determination of polymers, three-dimensional computer molecular modeling, rational drug design, and immunomodulatory polymers. In particular the invention is directed to immunomodulatory polymers, as well as to methods for designing, selecting, and screening therapeutic agents having immunomodulatory activity. | 12-24-2009 |
| 20090312675 | SUB-ATMOSPHERIC PRESSURE CHAMBER FOR MECHANICAL ASSISTANCE OF BLOOD FLOW - A sub-atmospheric pressure treatment device may include a chamber, a vacuum source, a pulse sensor, and a controller. | 12-17-2009 |
| 20090270843 | MICROMECHANICAL FORCE DEVICES FOR WOUND HEALING ACCELERATION - An apparatus provides micromechanical forces on a wound bed to accelerate healing of a wound. The apparatus includes a pressure chamber having a substantially airtight plunger and an inlet fluidly connected to a first end of a conduit. A constant force spring is operatively connected to apply a constant force to the plunger. A suction cup is in fluid communication with a second end of the conduit. | 10-29-2009 |
| 20090247589 | Monocarboxylates for modifying macrophage function - The present invention is directed to methods of inhibiting the production of proinflammatory agents by macrophages by contacting the cells with a monocarboxylate such as nicotinic acid. The invention also includes methods of treating diseases that are associated with macrophage activation such as atherosclerosis; systemic lupus erythematosus; rheumatoid arthritis; inflammatory bowel disease; and diabetes mellitus. | 10-01-2009 |
| 20090192078 | METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 07-30-2009 |
| 20090175849 | NOTCH inhibition in the treatment or prevention of atherosclerosis - The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and for measuring levels of amount, function, or activity of NOTCH pathway components in biological samples. | 07-09-2009 |
| 20090162873 | GENE ENCODING A MULTIDRUG-RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell s susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance. | 06-25-2009 |
| 20090117117 | TARGETING ABCB5 FOR CANCER THERAPY - The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | 05-07-2009 |
| 20090110687 | COMPOSITIONS AND METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 04-30-2009 |
| 20090104617 | Diagnostic and Prognostic Tests - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided. | 04-23-2009 |
| 20090099102 | Ginkgolides in the Treatment and Prevention of Ovarian Cancer - The present invention is directed to pharmaceutical compositions and nutritional supplements that contain large amount of ginkgolides, particularly ginkgolide A or B, and for which, the other components normally found in | 04-16-2009 |
| 20090093511 | Mast cell stabilizers in the treatment of obesity - The present invention is directed to methods of treating or preventing the development of obesity by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing obesity. | 04-09-2009 |
| 20090089079 | System and method for determining whether to issue an alert to consider prophylaxis for a risk condition - Disclosed herein is a system and method for determining whether to issue an alert to consider prophylaxis (e.g., mechanical and/or pharmacological) with respect to a risk condition (e.g., risk of VTE, DVT and/or PE). One or more sources of patient information are queried to retrieve patient information for a set of patients. From this retrieved patient information, it is determined whether any risk factors of a set of risk factors are satisfied for each such patient. For each patient for which one or more risk factors are satisfied, a respective value and/or classification is assigned to each risk factor. The values and/or classifications are combined to produce a combined value, and it is determined from the combined value whether the patient has the risk condition. If the patient has the risk condition, an alert is issued (e.g., on a display screen) to a health care provider for consideration of prophylaxis. | 04-02-2009 |
| 20090068740 | AMORPHOUS CELL DELIVERY VEHICLE TREATED WITH PHYSICAL/PHYSICOCHEMICAL STIMULI - Provided are compositions and methods for in vitro generation and in vivo use of tissue for the repair of defective tissue, especially cartilage. Chondrocytes or other cells are cultured in vitro in a biodegradable amorphous carrier within the confines of a space bounded by a semi-permeable membrane with a molecular weight cut-off of greater than 100 kDa. The culture can be subjected to physical/physicochemical conditions that mimic in vivo conditions of the tissue in need of repair or replacement. In one embodiment the invention provides an amorphous preparation of chondrocytes and their extracellular products, suitable for injection. | 03-12-2009 |
| 20090054500 | Composition and methods useful in preventing cardiac hypertrophy - The present invention is directed to compositions and methods that can be used for preventing the hypertrophy of cardiac cells. The compositions and methods involve the use of compounds that lead to an increase in the cellular activity of the transcription factor CHF1. | 02-26-2009 |
| 20090053263 | Inhibitors of Enveloped Virus Infectivity - The present invention relates to treatment of infection by enveloped viruses through the use of papain-like cysteine protease inhibitors and kits thereof. Specifically, methods for treatment of filoviruses as well as other enveloped viruses such as Nipah, in particular using cathepsin inhibitors are described. | 02-26-2009 |
| 20090036415 | Identification and treatment of estrogen responsive prostate tumors - The present invention is directed to specific chromosomal rearrangements that are associated with prostate tumors that respond to compounds acting at estrogen receptors. Patients having the TMPRSS2-ERG fusion, may be treated with agonists of the estrogen beta receptor or antagonists of the estrogen alpha receptor. | 02-05-2009 |
| 20080302950 | System and Method for Performing Single Photon Emission Computed Tomography (Spect) with a Focal-Length Cone-Beam Collimation - A system and method are provided for obtaining data that may be used to generate images of a brain or other bodily organ. The system can include a pair of detecting arrangements and a collimating arrangement associated with each detecting arrangement. A first collimating arrangement can include a cone-beam collimating arrangement having a focal point located within the brain or other organ being imaged. A second collimating arrangement can include a fan-beam collimating arrangement having a focal length selected such that the organ being imaged lies within its field of view to ensure data sufficiency. Cone-beam collimating arrangements having improved hole geometries can also be utilized to provide further increases in imaging sensitivity. | 12-11-2008 |
| 20080279866 | Induction of immunosuppression by inhibition of ATM - The present invention is directed to methods of inducing immunosuppression in a patient by administering an inhibitor of the enzyme Ataxia telangiectasia mutated (Atm). The method may be used as a treatment for allergies, autoimmune diseases or lymphomas. It may also be used to prevent organ rejection in transplant patients and to treat or prevent graft versus host disease. | 11-13-2008 |
| 20080275409 | WOUND HEALING DEVICE - Methods and devices transmit micromechanical forces locally on the millimeter to micron scale for promoting wound healing. Micromechanical forces can selectively be applied directly to tissue, in some embodiments, by using microchambers fluidically connected to microchannels. Each chamber, or in some cases, group of chambers, may be associated with a valve to control vacuum pressure, positive pressure, liquid delivery, and/or liquid removal from each chamber or group of chambers. Application of embodiments of the invention may shorten wound-healing time, reduce costs of therapy, enable restoration of functional tissue, and reduce the need for more invasive therapies, including surgery. | 11-06-2008 |
| 20080241150 | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 - The present invention relates to a LNR-HD domain of the Notch receptor and methods of use. The method for expression and structural determination of the LNR-HD domain is described. | 10-02-2008 |
| 20080220169 | Parylene-C Stencils - A reuseable microfabrication stencil is described that can be reversibly sealed on various substrates to pattern biomolecules and biomaterials such as proteins and cells. The stencil may be used for the generation of both static and dynamic co-cultures, and cell aggregates. A multilayer stencil is described that can be used in biological patterning and used to create static and dynamic co-cultures and cell aggregates. Processes for producing and using the microfabrication stencils are also described. | 09-11-2008 |
| 20080214487 | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents - A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form. | 09-04-2008 |
| 20080207753 | Analogues of lipid mediators derived from omega-3 PUFAs and methods of use - The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ω-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases. | 08-28-2008 |
